6MI2 image
Entry Detail
PDB ID:
6MI2
Keywords:
Title:
Structure of the human 4-1BB / Utomilumab Fab complex
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2018-09-19
Release Date:
2018-11-21
Method Details:
Experimental Method:
Resolution:
2.72 Å
R-Value Free:
0.27
R-Value Work:
0.23
R-Value Observed:
0.24
Space Group:
I 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Utomilumab Fab heavy chain
Chain IDs:A, C (auth: D)
Chain Length:230
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Utomilumab Fab lambda chain
Chain IDs:B, D (auth: E)
Chain Length:214
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Tumor necrosis factor receptor superfamily member 9
Chain IDs:E (auth: F), F (auth: C)
Chain Length:145
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.
Nat Commun 9 4679 4679 (2018)
PMID: 30410017 DOI: 10.1038/s41467-018-07136-7

Abstact

4-1BB (CD137, TNFRSF9) is an inducible costimulatory receptor expressed on activated T cells. Clinical trials of two agonist antibodies, utomilumab (PF-05082566) and urelumab (BMS-663513), are ongoing in multiple cancer indications, and both antibodies demonstrate distinct activities in the clinic. To understand these differences, we solved structures of the human 4-1BB/4-1BBL complex, the 4-1BBL trimer alone, and 4-1BB bound to utomilumab or urelumab. The 4-1BB/4-1BBL complex displays a unique interaction between receptor and ligand when compared with other TNF family members. Furthermore, our ligand-only structure differs from previously published data. Utomilumab, a ligand-blocking antibody, binds 4-1BB between CRDs 3 and 4. In contrast, urelumab binds 4-1BB CRD-1, away from the ligand binding site. Finally, cell-based assays demonstrate utomilumab is a milder agonist than urelumab. Collectively, our data provide a deeper understanding of the 4-1BB signaling complex, providing a template for future development of next generation 4-1BB targeted biologics.

Legend

Protein

Chemical

Disease

Primary Citation of related structures